Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:11 2024-04-19 am EDT			5-day change	1st Jan Change
85.53 ^CHF	+1.19%		-0.66%	+0.78%

Apr. 19	US FDA mandates label updates on CAR-T cancer therapies	RE
Apr. 18	NOVARTIS AG : UBS reiterates its Buy rating	ZD

NOVARTIS AG : UBS maintains a Buy rating

January 14, 2021 at 05:56 am EST

UBS analyst Laura Sutcliffe maintains his Buy rating on the stock. The target price is revised downwards from CHF 99 to CHF 96.

Latest news about Novartis AG

US FDA mandates label updates on CAR-T cancer therapies	Apr. 18	RE
NOVARTIS AG : UBS reiterates its Buy rating	Apr. 18	ZD
TotalEnergies: shareholders want to separate powers	Apr. 18	CF
NOVARTIS AG : Deutsche Bank maintains a Buy rating	Apr. 18	ZD
Novartis' Multiple Sclerosis Drug Shows Sustained Efficacy for Up to Six Years	Apr. 17	MT
Novartis: positive efficacy data in MS	Apr. 17	CF
Novartis Kesimpta(R) six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis	Apr. 17	DJ
Novartis' Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB?s Bimzelx Poised to Further Disrupt the Market	Apr. 16	CI
Novartis reports positive interim results for Fabhalta	Apr. 16	CF
Novartis' Investigational Kidney Disease Drug Shows Reduced Disease Marker in Late-stage Trial	Apr. 15	MT
Health Care Ticks Down Amid Rotation From Rate-Sensitive Sectors -- Health Care Roundup	Apr. 15	DJ
Novartis' Fabhalta Found to Lower Disease Marker in Kidney Disease Patients	Apr. 15	MT
Novartis Gets Priority Review for Kidney Disease Treatment	Apr. 15	DJ
New Novartis Fabhalta(R) (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)	Apr. 15	DJ
Novartis Presents Results from Pre-Specified Interim Analysis of the Phase III APPLAUSE-IgAN study of Fabhalta	Apr. 15	CI
Novartis Secures Exclusive Licensing Deal with Arvinas for Prostate Cancer Drug	Apr. 12	MT
Health Care Slips on Risk Bias -- Health Care Roundup	Apr. 11	DJ
Trending : Novartis Begins Tender Offer for MorphoSys Shares	Apr. 11	DJ
Novartis: licensing agreement in prostate cancer	Apr. 11	CF
Novartis: MorphoSys Board recommends tender offer	Apr. 11	CF
MorphoSys Board Supports Norvartis' Buyout Offer as Tender Period Begins	Apr. 11	MT
Morphosys management bodies recommend acceptance of Novartis takeover bid	Apr. 11	DP
Arvinas Agrees to License Prostate Cancer Treatment, Sell AR-V7 Program to Novartis	Apr. 11	MT
Arvinas, Novartis in ARV-766 Prostate Cancer License Pact	Apr. 11	DJ
Novartis licenses Arvinas' cancer drug for up to $1 billion	Apr. 11	RE

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).

Sector

Pharmaceuticals

Calendar

2024-04-23 - Q1 2024 Earnings Release

Related indices

SMI , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

NOVARTIS : Novartis on course to set new highs

February 20, 2024 at 11:30 am EST

Novartis AG : Sandoz takes its first steps on the stock exchange

October 04, 2023 at 10:32 am EDT

More Strategies

Ratings for Novartis AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

94.11 USD

Average target price

106.1 USD

Spread / Average Target

+12.72%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVARTIS AG	+0.78%	203B
ELI LILLY AND COMPANY	+24.60%	672B
NOVO NORDISK A/S	+24.08%	550B
JOHNSON & JOHNSON	-5.63%	351B
MERCK & CO., INC.	+15.37%	317B
ABBVIE INC.	+7.38%	292B
ASTRAZENECA PLC	+3.26%	211B
PFIZER, INC.	-9.69%	144B
AMGEN INC.	-6.63%	141B
SANOFI	-3.20%	113B

Other Pharmaceuticals

Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

NOVARTIS AG : UBS maintains a Buy rating

Latest news about Novartis AG

Chart Novartis AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Novartis AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals